BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.nebraska.edu

Clinical Trials

Analysis of Lipid Biomarkers of Exposure and Host Response

Not Applicable

Terminated

Conditions: Cigarette Smoking

Interventions: Drug: nicotine polacrilex, transdermal system or inhaler

First Posted Date: 2007-06-28

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Target Recruit Count: 24

Registration Number: NCT00493831

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Talabostat in Treating Patients With Metastatic Kidney Cancer

Phase 2

Withdrawn

Conditions: Kidney Cancer

Interventions: Drug: talabostat mesylate
Biological: enzyme inhibitor therapy
Diagnostic Test: flow cytometry
Diagnostic Test: laboratory biomarker analysis
Biological: non-specific immune-modulator therapy

First Posted Date: 2007-06-21

Last Posted Date: 2023-08-22

Lead Sponsor: University of Nebraska

Registration Number: NCT00489710

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Phase 1

Completed

Conditions: Extrahepatic Bile Duct Cancer
Gallbladder Cancer
Gastric Cancer
Liver Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: carboplatin
Drug: epirubicin hydrochloride
Genetic: microarray analysis
Genetic: polymorphism analysis
Other: pharmacological study

First Posted Date: 2007-06-14

Last Posted Date: 2024-01-03

Lead Sponsor: University of Nebraska

Target Recruit Count: 46

Registration Number: NCT00486356

Locations: 🇺🇸
University of Nebraska Medical Center, Eppley Cancer Center, Omaha, Nebraska, United States

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Gefitinib plus etoposide

First Posted Date: 2007-06-07

Last Posted Date: 2023-09-13

Lead Sponsor: University of Nebraska

Target Recruit Count: 26

Registration Number: NCT00483561

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: gemcitabine hydrochloride
Drug: imatinib mesylate
Genetic: mutation analysis
Genetic: nucleic acid sequencing
Genetic: polymerase chain reaction

First Posted Date: 2007-06-07

Last Posted Date: 2023-09-14

Lead Sponsor: University of Nebraska

Target Recruit Count: 13

Registration Number: NCT00483366

Locations: 🇺🇸
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: docetaxel
Drug: goserelin
Radiation: intensity-modulated radiation therapy

First Posted Date: 2007-06-05

Last Posted Date: 2023-11-24

Lead Sponsor: University of Nebraska

Target Recruit Count: 9

Registration Number: NCT00482807

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Analysis of Aldehyde Biomarkers of Exposure and Host Response

Not Applicable

Terminated

Conditions: Smoking Cessation

Interventions: Drug: nicotine polacrilex
Drug: nicotine transdermal system
Drug: nicotine inhaler

First Posted Date: 2007-06-05

Last Posted Date: 2023-09-07

Lead Sponsor: University of Nebraska

Target Recruit Count: 35

Registration Number: NCT00482690

Locations: 🇺🇸
Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Validation of Biomarkers of Exposure and Host Response

Not Applicable

Completed

Conditions: Cigarette Smoker

First Posted Date: 2007-05-02

Last Posted Date: 2023-08-31

Lead Sponsor: University of Nebraska

Target Recruit Count: 60

Registration Number: NCT00468234

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Vascular Risk After Kidney Transplantation

Completed

Conditions: Cardiovascular Disease
Chronic Kidney Disease
Diabetes
Hyperparathyroidism
Vitamin D Deficiency

First Posted Date: 2006-09-11

Last Posted Date: 2023-10-02

Lead Sponsor: University of Nebraska

Target Recruit Count: 338

Registration Number: NCT00374595

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

Phase 4

Completed

Conditions: Attention Deficit Disorder With Hyperactivity

Interventions: Drug: Atomoxetine
Drug: Placebo
Behavioral: Parent Training

First Posted Date: 2005-11-16

Last Posted Date: 2023-10-02

Lead Sponsor: University of Nebraska

Target Recruit Count: 93

Registration Number: NCT00254462

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy